Titre : Organismes de services de gestion

Organismes de services de gestion : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostate
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Organismes de services de gestion : Questions médicales les plus fréquentes", "headline": "Organismes de services de gestion : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Organismes de services de gestion : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-03", "dateModified": "2025-02-28", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Organismes de services de gestion" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pratique professionnelle", "url": "https://questionsmedicales.fr/mesh/D011364", "about": { "@type": "MedicalCondition", "name": "Pratique professionnelle", "code": { "@type": "MedicalCode", "code": "D011364", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N04.452.758" } } }, "about": { "@type": "MedicalCondition", "name": "Organismes de services de gestion", "alternateName": "Management Service Organizations", "code": { "@type": "MedicalCode", "code": "D021661", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Aminu K Bello", "url": "https://questionsmedicales.fr/author/Aminu%20K%20Bello", "affiliation": { "@type": "Organization", "name": "Division of Nephrology and Immunology, Department of Medicine, University of Alberta Edmonton, Alberta, Canada." } }, { "@type": "Person", "name": "Vivekanand Jha", "url": "https://questionsmedicales.fr/author/Vivekanand%20Jha", "affiliation": { "@type": "Organization", "name": "George Institute for Global Health, University of New South Wales, New Delhi, India." } }, { "@type": "Person", "name": "Adeera Levin", "url": "https://questionsmedicales.fr/author/Adeera%20Levin", "affiliation": { "@type": "Organization", "name": "Nephrology Division, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada." } }, { "@type": "Person", "name": "Marcello Tonelli", "url": "https://questionsmedicales.fr/author/Marcello%20Tonelli", "affiliation": { "@type": "Organization", "name": "Department of Medicine, University of Calgary, Calgary, Alberta, Canada." } }, { "@type": "Person", "name": "Syed Saad", "url": "https://questionsmedicales.fr/author/Syed%20Saad", "affiliation": { "@type": "Organization", "name": "Department of Medicine, University of Alberta, Edmonton, Alberta, Canada." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Presence of HPV in prostate tissue from patients submitted to prostate biopsy.", "datePublished": "2023-01-13", "url": "https://questionsmedicales.fr/article/36651430", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/acb371205" } }, { "@type": "ScholarlyArticle", "name": "Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review.", "datePublished": "2022-07-13", "url": "https://questionsmedicales.fr/article/35696302", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/bju.15823" } }, { "@type": "ScholarlyArticle", "name": "Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.", "datePublished": "2023-05-26", "url": "https://questionsmedicales.fr/article/37271051", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cmpb.2023.107624" } }, { "@type": "ScholarlyArticle", "name": "Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.", "datePublished": "2023-03-14", "url": "https://questionsmedicales.fr/article/36917412", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11255-023-03531-2" } }, { "@type": "ScholarlyArticle", "name": "Prostatic artery embolization compared to transurethral resection of the prostate and prostatic urethral lift: a real-world population-based study.", "datePublished": "2022-12-04", "url": "https://questionsmedicales.fr/article/36463348", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00345-022-04218-6" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Administration des services de santé", "item": "https://questionsmedicales.fr/mesh/D006298" }, { "@type": "ListItem", "position": 3, "name": "Organisation et administration", "item": "https://questionsmedicales.fr/mesh/D009934" }, { "@type": "ListItem", "position": 4, "name": "Pratique professionnelle", "item": "https://questionsmedicales.fr/mesh/D011364" }, { "@type": "ListItem", "position": 5, "name": "Organismes de services de gestion", "item": "https://questionsmedicales.fr/mesh/D021661" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Organismes de services de gestion - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Organismes de services de gestion", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Organismes de services de gestion", "description": "Comment identifier un OSG ?\nQuels services offrent les OSG ?\nQuels sont les types d'OSG ?\nComment évaluer l'efficacité d'un OSG ?\nQuels outils utilisent les OSG ?", "url": "https://questionsmedicales.fr/mesh/D021661?mesh_terms=Prostate&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Organismes de services de gestion", "description": "Quels signes indiquent un besoin d'OSG ?\nComment reconnaître une mauvaise gestion ?\nQuels impacts d'une mauvaise gestion ?\nQuels symptômes d'une surcharge administrative ?\nComment détecter des erreurs fréquentes ?", "url": "https://questionsmedicales.fr/mesh/D021661?mesh_terms=Prostate&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Organismes de services de gestion", "description": "Comment prévenir les erreurs de gestion ?\nQuelles pratiques recommandées pour les OSG ?\nComment assurer la conformité réglementaire ?\nQuels outils pour la prévention des risques ?\nComment sensibiliser le personnel aux OSG ?", "url": "https://questionsmedicales.fr/mesh/D021661?mesh_terms=Prostate&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Organismes de services de gestion", "description": "Comment un OSG améliore-t-il la gestion ?\nQuels outils de gestion sont recommandés ?\nComment former le personnel à l'OSG ?\nQuels sont les bénéfices d'un OSG ?\nComment évaluer un OSG ?", "url": "https://questionsmedicales.fr/mesh/D021661?mesh_terms=Prostate&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Organismes de services de gestion", "description": "Quelles complications d'une mauvaise gestion ?\nComment une mauvaise gestion affecte-t-elle les soins ?\nQuels risques d'une surcharge administrative ?\nComment gérer les plaintes des patients ?\nQuelles conséquences d'une non-conformité ?", "url": "https://questionsmedicales.fr/mesh/D021661?mesh_terms=Prostate&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Organismes de services de gestion", "description": "Quels facteurs augmentent le besoin d'OSG ?\nComment la technologie influence-t-elle les OSG ?\nQuels sont les risques liés à la gestion interne ?\nComment le marché affecte-t-il les OSG ?\nQuels impacts des changements réglementaires ?", "url": "https://questionsmedicales.fr/mesh/D021661?mesh_terms=Prostate&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier un OSG ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un OSG est identifié par ses services de gestion administrative et de soutien aux pratiques médicales." } }, { "@type": "Question", "name": "Quels services offrent les OSG ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les OSG offrent des services tels que la facturation, la gestion des ressources humaines et le soutien technologique." } }, { "@type": "Question", "name": "Quels sont les types d'OSG ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les types d'OSG incluent ceux spécialisés en facturation, en gestion de la qualité et en conformité réglementaire." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité d'un OSG ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité d'un OSG peut être évaluée par des indicateurs de performance tels que la satisfaction des clients et la réduction des coûts." } }, { "@type": "Question", "name": "Quels outils utilisent les OSG ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les OSG utilisent des logiciels de gestion, des systèmes de facturation et des plateformes de communication." } }, { "@type": "Question", "name": "Quels signes indiquent un besoin d'OSG ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des signes incluent une surcharge administrative, des erreurs fréquentes et une mauvaise gestion du temps." } }, { "@type": "Question", "name": "Comment reconnaître une mauvaise gestion ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Une mauvaise gestion se manifeste par des retards dans les paiements, des plaintes de patients et des audits défavorables." } }, { "@type": "Question", "name": "Quels impacts d'une mauvaise gestion ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les impacts incluent une baisse de la qualité des soins, une insatisfaction des patients et des pertes financières." } }, { "@type": "Question", "name": "Quels symptômes d'une surcharge administrative ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent le stress du personnel, des délais prolongés et une communication inefficace." } }, { "@type": "Question", "name": "Comment détecter des erreurs fréquentes ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des audits réguliers et des retours d'expérience des employés aident à détecter les erreurs fréquentes." } }, { "@type": "Question", "name": "Comment prévenir les erreurs de gestion ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par des formations régulières, des audits et l'utilisation de technologies adaptées." } }, { "@type": "Question", "name": "Quelles pratiques recommandées pour les OSG ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les pratiques recommandées incluent la standardisation des processus et la mise en place de contrôles internes." } }, { "@type": "Question", "name": "Comment assurer la conformité réglementaire ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Assurer la conformité nécessite des audits réguliers et une mise à jour continue des connaissances réglementaires." } }, { "@type": "Question", "name": "Quels outils pour la prévention des risques ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des outils comme les logiciels de gestion des risques et les plateformes de communication sont utiles." } }, { "@type": "Question", "name": "Comment sensibiliser le personnel aux OSG ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "La sensibilisation peut se faire par des formations, des réunions d'équipe et des bulletins d'information." } }, { "@type": "Question", "name": "Comment un OSG améliore-t-il la gestion ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Un OSG améliore la gestion en optimisant les processus, réduisant les coûts et augmentant l'efficacité." } }, { "@type": "Question", "name": "Quels outils de gestion sont recommandés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des outils comme les logiciels de gestion de cabinet et les systèmes de facturation sont recommandés." } }, { "@type": "Question", "name": "Comment former le personnel à l'OSG ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La formation peut inclure des ateliers, des sessions de coaching et des modules en ligne sur les outils de gestion." } }, { "@type": "Question", "name": "Quels sont les bénéfices d'un OSG ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les bénéfices incluent une meilleure gestion des ressources, une réduction des coûts et une satisfaction accrue des patients." } }, { "@type": "Question", "name": "Comment évaluer un OSG ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par des indicateurs de performance, des retours d'expérience et des audits réguliers." } }, { "@type": "Question", "name": "Quelles complications d'une mauvaise gestion ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des pertes financières, des plaintes de patients et des sanctions réglementaires." } }, { "@type": "Question", "name": "Comment une mauvaise gestion affecte-t-elle les soins ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut entraîner des retards dans les soins, une qualité inférieure et une insatisfaction des patients." } }, { "@type": "Question", "name": "Quels risques d'une surcharge administrative ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent le burnout du personnel, des erreurs de traitement et une communication défaillante." } }, { "@type": "Question", "name": "Comment gérer les plaintes des patients ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des plaintes nécessite une écoute active, une réponse rapide et des actions correctives." } }, { "@type": "Question", "name": "Quelles conséquences d'une non-conformité ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les conséquences incluent des amendes, des pertes de licence et une réputation ternie." } }, { "@type": "Question", "name": "Quels facteurs augmentent le besoin d'OSG ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent la taille de la pratique, la complexité des opérations et les changements réglementaires." } }, { "@type": "Question", "name": "Comment la technologie influence-t-elle les OSG ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "La technologie influence les OSG en améliorant l'efficacité, la communication et la gestion des données." } }, { "@type": "Question", "name": "Quels sont les risques liés à la gestion interne ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent le manque de formation, la résistance au changement et des processus obsolètes." } }, { "@type": "Question", "name": "Comment le marché affecte-t-il les OSG ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Les fluctuations du marché peuvent influencer la demande de services et la rentabilité des OSG." } }, { "@type": "Question", "name": "Quels impacts des changements réglementaires ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les changements réglementaires peuvent nécessiter des ajustements rapides et des formations supplémentaires." } } ] } ] }

Sources (10000 au total)

Presence of HPV in prostate tissue from patients submitted to prostate biopsy.

Prostate cancer (PCa) is the second most frequent cancer among men in the Western population. Infections, such as the one caused by the human papillomavirus (HPV), have been shown to promote inflammat... Prostate tissue fragments were collected by prostate biopsy and subjected to polymerase chain reaction with primers for the HPV L1 gene to identify the presence of the virus.... Among 162 patients, 10 (6.2%) had HPV and in 152 (93.8%) HPV was not identified in prostate biopsies. HPV was detected in 7/95 (7.4%) of patients with PCa, in 2/55 (3.6%) of patients without PCa, and ... There were no significant levels of HPV L1 protein in prostate tissue. The findings suggest the absence of HPV oncogenic activity in the prostate tissue of patients with PCa....

Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review.

To assess the effects of prostatic arterial embolisation (PAE) compared to other procedures for treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).... We included randomised controlled trials (RCTs), as well as non-randomised studies (NRSs) enrolling men with BPH undergoing PAE vs other surgical interventions via a comprehensive search up until 8 No... We found data to inform two comparisons: PAE vs transurethral resection of prostate (TURP; six RCTs and two NRSs), and PAE vs sham (one RCT). This abstract focuses on the primary outcomes in a compari... Compared to TURP, the impact on urological symptoms and QoL improvement as perceived by patients appears to be similar. This review did reveal major uncertainty as to how major adverse events compare....

Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.

With emerging evidence to improve prostate cancer (PCa) screening, multiparametric magnetic prostate imaging is becoming an essential noninvasive component of the diagnostic routine. Computer-aided di... We collected 1647 fine-grained biopsy-confirmed findings, including Gleason scores and prostatitis, to form a training dataset. In our experimental framework for lesion detection, all models utilized ... An optimal model configuration with fine class granularity (prostatitis included) and OHE has scored the lesion-wise partial Free-Response Receiver Operating Characteristic (FROC) area under the curve... This paper examines several configurations for model training in the biparametric MRI setup and proposes optimal value ranges. It also shows that the fine-grained class configuration, including prosta...

Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.

To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced n... The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients wit... In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with ... A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biops...

Prostatic artery embolization compared to transurethral resection of the prostate and prostatic urethral lift: a real-world population-based study.

There are growing interests for minimally invasive surgical techniques (MISTs) for the treatment of benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS). Prostatic artery ... We present an observational population-based study of 12,902 men with BPH in New York State who received PAE, TURP, and PUL in outpatient and ambulatory surgery settings from 2014 to 2018. For short-t... Of 12 902 men, 335 had PAE, 11,205 had TURP, and 1362 had PUL. PAE patients had the highest 30-day (19.9%) and 90-day (35.6%) risks of readmission to inpatient or ER (p < 0.01). Non-specific abdominal... In a real-world population, PAE was associated with the most frequent 30-day and 90-day readmission to inpatient or ER and the highest retreatment rate among all surgical techniques even when controll...

Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?

Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investiga... Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively qu... Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (114... The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger canc...

Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?

The paradigm of focal therapy's role in metastatic patients is being challenged by evolving attitudes and emerging data. At the current time, specifically regarding prostate cancer, does the evidence ... We searched the literature via PubMed, MEDLINE, and Embase for studies from 2014 to the present addressing focal therapy with non-palliative intent in metastatic prostate cancer patients, emphasizing ... Current evidence is strongest, and in our opinion practice-changing, for prostate-directed RT in de novo metastatic patients with low metastatic burden. Metastasis-directed therapy with SBRT is consis...